Iduronate-2-sulfatase gene therapy

N/A

Report date: 2022/02/17 14:08:56

Base Information

Drug NameIduronate-2-sulfatase gene therapy

Drug Alias NameHunter syndrome gene therapy

ClassificationCell and gene therapy > Cell therapy > Donor > AutologousCell and gene therapy > Gene therapyCell and gene therapy > Cell therapy > Stem cell therapy > Hematopoietic stem cells therapy

Mechanisms of ActionIduronate-2-sulfatase gene transference

TargetsIduronate-2-sulfatase

Therapy Area/IndicationsMucopolysaccharidosis II

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusDiscontinued (Phase 2 Clinical)

Highest Status in ChinaN/A

Originator CompaniesUniversity Of Minnesota

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesUniversity Of Minnesota

Active IndicationsN/A

Inactive IndicationsMucopolysaccharidosis II

Other Information

ATC CodeN/A